Sophie Payne

Sep 25, 2024 | aiche.onlinelibrary.wiley.com | Tianruo Guo |Ewa M. Goldys |Sophie Payne |Selena Chia

Our study addresses the limitations of fecal calprotectin detection in diagnosing and monitoring inflammatory bowel disease (IBD). We developed a portable, tube-based CRISPR/Cas assay for point-of-care testing of calprotectin, with a detection range of 1–10,000 ng/ml. Validated in a preclinical rodent model of ulcerative colitis (UC), this assay showed 2–3 times higher calprotectin levels in UC samples compared to healthy controls.

Feb 5, 2024 | mdpi.com | Neva Kandzija |Sophie Payne |William R. Cooke |Faheem Seedat

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Jun 16, 2023 | frontiersin.org | Dorota Szumska |Jacinta Kalisch-Smith |Sophie Payne

B. Petrelli1, A. Oztürk1, M. Pind1, H. Ayele1, A. Fainsod2 and G. G.

Apr 12, 2023 | journals.plos.org | Sophie Payne |Casey Lippmeier |Jeremy Dahmen |Arjan Vermeulen

Loading metrics Open Access Peer-reviewedResearch Article AbstractThe emergence of COVID-19 as a global pandemic had sharply illustrated the limitations of research and development pipelines and scaled manufacturing. Although existing vaccines were created in record time, global deployment remains limited by regional production scales.

Mar 9, 2023 | medium.com | Sophie Payne

In 2021, we published a commitment to do more to address the prevalent diversity, equity and inclusion issues in venture capital, while remaining transparent in the process. Two years on, we continue to actively track and share the actions we are taking to promote diversity, equity and inclusion (DEI) across our team and our portfolio companies.